N
Nicola Inzerilli
Publications - 6
Citations - 367
Nicola Inzerilli is an academic researcher. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 1, co-authored 1 publications receiving 294 citations.
Papers
More filters
Journal ArticleDOI
PTEN: Multiple Functions in Human Malignant Tumors
Michele Milella,Italia Falcone,Fabiana Conciatori,Ursula Cesta Incani,Anais Del Curatolo,Nicola Inzerilli,Carmen Nuzzo,Vanja Vaccaro,Sabrina Vari,Francesco Cognetti,Ludovica Ciuffreda +10 more
TL;DR: The current understanding of the biological role of PTEN, how PTEN expression and activity are regulated, and the consequences ofPTEN dysregulation in human malignant tumors are discussed.
Journal ArticleDOI
Molecular Analysis of Luminal Androgen Receptor Reveals Activated Pathways and Potential Therapeutic Targets in Breast Cancer
Stefania Stella,Silvia Rita Vitale,Michele Massimino,Gianmarco Motta,Claudio Longhitano,K. Lanzafame,Federica Martorana,Carmine Fazzari,Giada Maria Vecchio,Elena Tirrò,Nicola Inzerilli,Rosaria Carciotto,Livia Manzella,Michele Caruso,Paolo Vigneri +14 more
TL;DR: Findings confirm a role for PI3K/AKT/mTOR signaling in the pathogenesis of LAR breast cancers and indicate that targeting this pathway, along with ERBB2 mutations, may represent an additional therapeutic strategy which deserves further exploration in larger studies.
Journal ArticleDOI
Non-Hodgkin Lymphoma Developed Shortly after mRNA COVID-19 Vaccination: Report of a Case and Review of the Literature
Luigi Cavanna,Sergio Ottavio Grassi,Livia Ruffini,Emanuele Michieletti,Egidio Carella,Dante Palli,A. Zangrandi,Nicola Inzerilli,Patrizia Bernuzzi,Camilla Di Nunzio,Chiara Citterio +10 more
TL;DR: In this paper , a 66-year-old man with stage II non-Hodgkin lymphoma was treated with chemotherapy and a scheme of Brentuximab Vedotin, Cyclophosphamide, Doxorubicin and Prednisone (BV-CHP) for six cycles and is now well and in complete remission.
Journal ArticleDOI
Next generation sequencing in a cohort of patients with rare sarcoma histotypes: A single institution experience.
Elena Tirrò,Federica Martorana,Giovanni Micale,Nicola Inzerilli,Rosaria Carciotto,Chiara Romano,Claudio Longhitano,Gianmarco Motta,K. Lanzafame,Stefania Stella,Michele Massimino,Silvia Rita Vitale,Lucia Salvatorelli,Gaetano Magro,Livia Manzella,Paolo Vigneri +15 more
TL;DR: In this article , the authors analyzed 18 samples from 11 low-incidence sarcomas using NGS technology and used an in-silico prediction tool to reclassify variants of unknown significance and looked for potentially druggable alterations to match with targeted therapies.
Journal ArticleDOI
Additional biological and clinical characteristics to refine International Metastatic RCC Database Consortium (IMDC) prognostic/predictive assessment in metastatic renal cell carcinoma (mRCC).
Ilaria Zampiva,Sara Merler,Nicola Inzerilli,Francesca Zacchi,Stefano Manduca,Sarah Pafumi,Michela Piacentini,Stefano Marletta,Ursula Cesta Incani,Lorena Torroni,Roberta Vesentini,Pierpaolo Marchetti,Emanuela Fantinel,Andrea Zivi,Anna Caliò,Matteo Brunelli,Giuseppe Verlato,Michele Milella +17 more
TL;DR: In this article , a retrospective cohort of 113 mRCC patients treated at the Verona University Hospital Trust between 2013 and 2021 was explored to identify additional clinical prognostic factors for OS to complement IMDC score.